Novo Nordisk(US:NVO) GLP1减重宝典·2025-06-23 08:47Core Viewpoint - Novo Nordisk's experimental weight loss drug Amycretin shows significant efficacy in early clinical trials, with weight loss of up to 24% in overweight and obese adults, laying the groundwork for a large Phase III trial planned for next year [2][6]. Group 1: Drug Efficacy and Mechanism - Amycretin is administered either weekly via injection or daily orally, with gastrointestinal side effects similar to other recently launched weight loss drugs [3]. - The drug operates through a dual mechanism, mimicking the gut hormone GLP-1 and activating the appetite-suppressing hormone amylin, which may contribute to its enhanced weight loss effects [6]. - In injection trials, patients receiving 20 mg of Amycretin weekly lost an average of 22% of their weight over 36 weeks, while those on a 60 mg dose lost 24.3% [7]. Group 2: Comparative Analysis and Future Research - In oral trials, participants increased their dosage from 3 mg to a maximum of 100 mg over 12 weeks, with those on 50 mg losing an average of 10.4% and those on the highest dose losing 13.1% [7]. - The weight loss trend did not plateau at the end of the trial, suggesting that longer-term treatment may yield greater weight loss [7]. - Experts emphasize the need for direct comparative studies between GLP-1 drugs like semaglutide and new drugs like Amycretin to clarify their relative value and positioning in obesity treatment [7].